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ABSTRACT
Introduction: Delayed diagnosis of type 2 diabetes mellitus (T2D) increases the risk of presenting late with microvas-
cular complications due to untreated long-standing hyperglycaemia. This study aimed to determine the prevalence 
of microvascular complications in newly diagnosed T2D patients in primary healthcare clinics. Methods: This was 
a cross-sectional study carried out in three government primary healthcare clinics in the state of Selangor, Malaysia. 
Malaysian aged 18 years and above with newly diagnosed T2D (≤ 6 months of diagnosis) were invited to partic-
ipate in the study. Data collected included the sociodemographic characteristic and the clinical profile (weight, 
height, waist circumference, blood pressure, lipid, glycaemic, urine albumin, microalbuminuria and renal profile). 
The assessment of nephropathy, peripheral neuropathy and retinopathy were performed using standard protocol. 
Multivariate logistic regression analysis was used to identify the significant factors that contribute to the presence 
of microvascular complications. Results: A total of 162 newly diagnosed patients were recruited. The majority was 
women (64%). The mean age was 51 (SD 11) years.  About one-third of the patients (27.7%) had developed at least 
one microvascular complication. Nephropathy was the commonest microvascular complication (19.2%), followed 
by peripheral neuropathy (8.6%) and retinopathy (6.5%). Poor glycaemic control was found to be a significant factor 
contributing to the presence of microvascular complications (OR 5.8, 95%CI:1.466, 23.288).  Conclusion: There 
is a high prevalence of microvascular complications among the newly diagnosed T2D. There is a need to develop 
appropriate strategies to increase the awareness and early detection of T2D. 
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INTRODUCTION
Diabetes mellitus is a major non-communicable disease 
and its prevalence has been increasing rapidly in low- 
and middle-income countries including Malaysia, a 
middle-income country (1, 2). The Malaysia National 
Health and Morbidity Survey (NHMS) had showed the 
increase of prevalence of type 2 diabetes (T2D) among 
adults aged 18 years and above, from 15.2% in 2011 to 
17.5% in 2015 (3, 4). 
Diabetes mellitus is known to cause significant morbidity 
and mortality. In 2012, it causes 1.5 million death in the 
world (2). It can lead to microvascular (nephropathy, 
retinopathy, and neuropathy) and macrovascular 
complications (ischemic heart disease, stroke and 
peripheral vascular disease) (2).
International Federation of Diabetes has reported that 1 
in 2 adults with diabetes is undiagnosed (1).  In Malaysia, 
90% of the diabetes is T2D and it was also found that 
more than half of these patients were undiagnosed 
(9.2% out of 17.5%), hence are at high risk of presenting 
late with complications due to untreated long-standing 
hyperglycaemia (4). 
Microvascular complications such as retinopathy, 
nephropathy and peripheral neuropathy are common in 
patients with T2D (1, 2).  The undiagnosed T2D is not a 
benign condition and significant of complications could 
have present at diagnosis or years before diagnosis (5). 
Literature has showed that there was high prevalence of 
microvascular complications among newly diagnosed 
T2D (6–8), for example nephropathy was present in 
50% of the newly diagnosed patients in one of the study 
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in India (6) and 24% in Pakistan (9). 
To our knowledge, there is paucity of data locally on 
the prevalence of microvascular complications among 
patients with newly diagnosed T2D in Malaysia. There 
was only one study examine reported the prevalence of 
microvascular complication from the tertiary teaching 
hospital-based clinic in Kelantan (8).  Our study aimed at 
assessing the prevalence of microvascular complications 
in newly diagnosed T2D at primary healthcare setting. A 
high prevalence of such complications, if documented 
will help to emphasise the need and importance of early 
screening for these complications at diagnosis in all 
newly diagnosed T2D and vigorous screening campaign 
to increase the awareness of public to undergo health 
check for early diagnosis of T2D.   The primary 
objective of this study was to determine the prevalence 
of microvascular complications and the secondary 
objective was to identify factors that contributed to the 
presence of microvascular complications.
MATERIALS AND METHODS
Study Design and Setting
A cross-sectional study was conducted for a study period 
of 6 months (1st July 2017 to 31st December 2017) in 
three government primary healthcare clinics located 
in the state of Selangor, Malaysia.  The government 
primary healthcare clinics were selected as majority of 
the patients with chronic diseases were treated in the 
government primary healthcare clinics due to affordable 
cost that was highly subsidized by the government (10). 
The diabetic care of all these three government primary 
healthcare clinics were managed by a diabetic team that 
consisted of family medicine specialists, medical officers 
and diabetic educators. These clinics were equipped 
with the facilities of fundus camera and laboratory 
services. Both oral anti-diabetic agents and insulin were 
available in these clinics. The attendances of patients 
with diabetes varied among three clinics, ranged from 
30 to 100 patients a day.
Study population 
Malaysian nationality of age 18 years and above with 
newly diagnosed T2D (≤ 6 months of diagnosis) were 
included in the study. Diagnosis was made based on the 
Malaysian Clinical Practice Guidelines of Management 
of Type 2 Diabetes Mellitus (11). Those with known 
history of congestive heart failure, renal disease or renal 
impairment, chronic liver disease, history of stroke 
affecting the legs, hypothyroidism and alcoholism were 
excluded from the study. Pregnant women and acutely 
ill patients who need emergency treatment were also 
excluded from the study. 
Sample size estimation
Sample size was calculated using Kish L. survey sampling 
(12), based on the prevalence of 8.3% and confidence 
interval of 95% from the previous study on risk factor 
of peripheral neuropathy among newly diagnosed 
T2D patients in primary care clinic at tertiary teaching 
hospital (8). We also added the non-response rate of 
30% to the calculated sample size which contributed to 
the total number of 152 patients.
Data collection
All newly diagnosed T2D patients who fulfilled the 
inclusion criteria were invited to participate in the 
study. Participants were approached at the registration 
counter that dedicated for giving out a diabetic checked 
book for all newly diagnosed patients. The diabetic 
checked book is a structured clinical record that 
includes the essential clinical monitoring checklist for 
diabetes management.  This counter was identified 
to be the place of recruitment as all newly diagnosed 
T2D patients would refer to this counter for getting the 
diabetic checked book.  Participants were explained 
about the study using participant information sheet. 
Written consent was obtained from those who agreed to 
participate in the study. 
Information about sociodemographic (age, race and 
occupation), lifestyle characteristics (smoking) and co-
morbidities (hypertension, dyslipidaemia) was obtained 
through face to face interview at the time of recruitment. 
The clinical parameters assessment (weight, height, 
waist circumference, blood pressure, eye and foot 
examinations) and laboratory investigations (glycated 
haemoglobin (HbA1c), fasting serum lipid including 
low-density lipoprotein cholesterol (LDL), high-density 
lipoprotein cholesterol (HDL), triglyceride (TG), urine 
albumin, microalbuminuria and renal profile) were 
performed at the subsequent follow up ranged from 2 
weeks to 3 months duration based on the appointment 
given by the treating physician.
Waist circumference was measured using measuring 
tape at the midpoint between the inferior margin of the 
last rib and top of the iliac crest in a horizontal plane. 
Clinical systolic blood pressure (SBP) and diastolic blood 
pressure (DBP) was measured in the sitting position using 
digital blood pressure monitor. All data was recorded 
using data collection sheet.
Assessment for Microvascular Complications
All participants were undergone a medical examination 
for assessment of peripheral neuropathy and fundus 
camera examination for retinopathy. These assessments 
were performed by trained and credentialed medical 
assistants or nurses in the diabetic care team. Laboratory 
tests (urine albuminuria or urine microalbuminuria 
and renal function) were carried out for assessment 
of nephropathy. The results were interpreted by the 
medical officers.
Retinopathy was assessed by using non-mydriatic 
fundus camera. It was examined for changes of diabetic 
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retinopathy and classified as non-proliferative diabetic 
retinopathy, proliferative diabetic retinopathy and 
maculopathy. Patients with cataract was excluded from 
the analysis of retinopathy and referred for to hospital 
for further assessment.
Peripheral neuropathy was assessed by using 10-g 
monofilament  and examinations of Achilles tendon 
reflex, pin prick, vibration sense by tuning fork (128Hz) 
and proprioception (11).  Presence of peripheral 
neuropathy was defined as abnormal monofilament test 
(no feeling in less than 8 out of 10 sites) and abnormal 
results of one of the above examinations.
Nephropathy was assessed by urine albumin, 
microalbuminuria and calculated GFR (e-GFR). It was 
defined as calculated GFR (e-GFR) less than 60 mL/min 
per 1.73m2 or persistent presence of albuminuria or 
microalbuminuria ≥30mg/mmol for 2 occasion 3 months 
apart (11, 13).  If the urine test was negative for albumin, 
urine microalbumin (UMA) for microalbuminuria was 
performed. If albuminuria or microalbuminuria was 
detected, a repeat test was performed at 3 months (13). 
The e-GFR was calculated using CKD-EPI formula (13).
Analysis
The dependent variables were the presence of 
microvascular complications i.e. retinopathy, peripheral 
neuropathy or nephropathy.  The independent variables 
were age, gender, race, smoking status, presence of co-
morbidities such as hypertension and dyslipidaemia, 
BMI status, blood pressure status, control of HbA1c, TG, 
LDL and HDL status.
The BMI was categorized as underweight (<18.5), 
normal (18.5-22.9), overweight (23.0-27.4) and obese 
(≥ 27.5) (11). The participants were considered to 
be hypertensive if they were taking antihypertensive 
medication (as documented in clinic records) or SBP ≥ 
135mmHg or DBP ≥ 75mmHg (11). Good glycaemic 
control was defined as HbA1c <6.5% (11). Diagnosis 
of dyslipidemia was made on the basis of fasting lipid 
profile, serum low density lipoprotein ≥ 2.6 mmol/L or 
serum triglycerides ≥1.7 mmol/L (11).
Data was entered and analysed using Statistical Program 
for Social Sciences (SPSS) 21 software. The categorical 
data was presented as frequency and percentage. The 
association between the dependent and independent 
variables was examined by Chi Square Test. Multivariate 
logistic regression was carried out using enter method 
to identify the significant factors that contributing to 
the microvascular complications. The confounding 
factors that were examined in the regression models 
were the age group, gender, race, comorbidities of 
hypertension, dyslipidaemia, smoking status, status 
of BMI, waist circumference and the control of blood 
pressure, glycaemic (HbA1c) and lipid profile (TG, 
HDL and LDL). The outcome was the presence of any 
microvascular complications. The level of significance 
was set at p< 0.05. Multivariate logistic regression model 
was presented as odds ratio (OR) with 95% confidence 
interval. 
Ethics 
Ethical approval for this study was obtained from the 
Medical Research & Ethics Committee, Ministry of 
Health Malaysia (NMRR-17-435-34672). 
 
RESULTS  
A total of 162 newly diagnosed T2D patients participated 
in the study. Majority was women (64%). The age 
ranged between 24 to 76 years with mean age of 51 (SD 
11) years.  About half of the patients had hypertension 
(62.4%) and dyslipidaemia (52.5%). Table I shows the 
sociodemographic characteristics of the patients.
Table I: Sociodemographic characteristic among patients with newly 
diagnosed type 2 Diabetes Mellitus
Variable Clinic 1 Clinic 2 Clinic 3
Total, n 
(%)
Gender) N=96 N=39 N=27 N=162
Male 35 (36.5) 15 (38.5) 8 (29.6) 58 (35.8)
Female 61 (63.5) 24 (61.5) 19 (70.4)
104 (64.2)
Age in years N=96 N=39 N=27 N=162
≤39 19 (19.8) 8 (20.6) 1 (3.7) 28 (17.3)
40-49 25 (26.0) 10 (25.6) 5 (18.5) 40 (24.7)
50-59 29 (30.2) 10 (25.6) 13 (48.2) 52 (32.1)
≥60 23 (24.0) 11 (28.2) 8 (29.6) 42 (25.9)
Race N=96 N=39 N=27 N=162
Malay 58 (60.4) 30 (76.9) 20 (74.1) 108 (66.7)
Chinese 17 (17.7) 5 (12.8) 4 (14.8) 26 (16.0)
Indian and 
others
21 (21.9) 4 (10.3) 3 (11.1) 28 (17.3)
Co-morbidities
Smoking 
11/84 
(13.1)
2/39 (5.1)
3/27 
(11.1)
16/150 
(10.7)
Hyperten-
sion 
50/96 
(52.1)
29 /39 
(74.4)
22/27 
(81.5)
101/162 
(62.4)
Dyslipid-
emia 
38/96 
(39.6)
29/39 
(74.4)
18/27 
(66.7)
85/162 
(52.5)
High proportion of the patients had poor clinical profile. 
About 90% of these patients were overweight or obese 
and near 80% of the patients did not achieve the target 
of blood pressure, LDL, HDL and glycaemic control 
(Table II).
About one third of the newly diagnosed patients (27.7%, 
45/162) had developed at least one microvascular 
complication. We found that nephropathy was the 
commonest microvascular complication (19.2%, 
28/146), followed by peripheral neuropathy (8.6%, 
14/162) and retinopathy (6.5%, 10/154). Two patients 
had retinopathy and nephropathy and one patient had 
all three microvascular complications. For retinopathy, 
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eight patients had non proliferative diabetic retinopathy 
(NPDR), one had proliferative diabetic retinopathy 
(PDR) and one had maculopathy.
There were 16 cases did not turn up for the 2nd sample 
collection of urine albumin/microalbumin after the 
initial positive of urine albumin/microalbumin and thus 
unable to confirm their status of nephropathy. There 
were three cases did not undergo the fundus camera 
examination and another 5 cases were having cataract.
There was no association found between the 
sociodemographic and clinical variables and the 
presence of nephropathy, retinopathy and peripheral 
neuropathy (Table III & IV) using the bivariate analysis. 
However, multivariate logistic regression analysis 
showed that glycaemic control was a significant factor 
contributing to the presence of at least one microvascular 
complication.  The odds of developing microvascular 
complications among patients with poor glycaemic 
control (HbA1c ≥6.5 %) was 5.8 times higher (OR 5.8, 
95%CI:1.466, 23.288) compared to patients who had 
good glycaemic control (HbA1c <6.5 %) (Table V).
DISCUSSION
Summary of principle findings
This study found that about one third of newly diagnosed 
T2D patients has developed at least one microvascular 
complication. The highest prevalence of microvascular 
complications was nephropathy (19.2%) followed by 
peripheral neuropathy (8.6%) and retinopathy (6.5%). 
Table II: Clinical profile among patients with newly diagnosed type 
2 Diabetes Mellitus 
Variable n (%)
BMI (N = 160)
<18.5 2(1.2)
18.5- 22.9 14 (8.8)
23.0-27.4 41(25.6)
≥ 27.5 103(64.4)
Waist circumference (N=160)
Achieved (women <80cm and men <90 cm) 18 (11.3)
Not achieved 142 (88.7)
Blood pressure N=162
≤135/75mmHg 29 (17.9)
>135/75mmHg 133 (82.1)
Lipid level (mmol/L)
Triglyceride (N=161)
≤1.7 96 (59.6)
>1.7 65 (40.4)
LDL (N=160)
≤ 2.6 31 (19.4)
>2.6 129 (80.6)
HDL(N=160)
Good control (man HDL>1, women HDL>1.2) 96 (60.0)
Poor control (man HDL≤1, women HDL≤1.2) 64 (40.0)
Glycaemic control (N=159)
HbA1c ≤ 6.5% 31 (19.5)
HbA1c > 6.5% 128 (80.5)
Table III: Association between sociodemographic and microvascular diabetic complications
Socio demo-
graphic charac-
teristics 
Nephropathy Retinopathy Peripheral Neuropathy
Yes
N=28
n (%)
No
N=118
n (%)
χ2 value P value Yes
N=10
n (%)
No
N=144
n (%)
χ2 value P value Yes
N =14
n (%)
No
N =148
n (%)
χ2 value P value
Age group 
(years)
≤ 39 4 (14.3) 19 (16.1)
NA NA
3(30.0) 25 (17.4)
NA NA
4 (28.6) 24(16.2)
NA NA
40- 49 5 (17.9) 28 (23.7) 3(30.0) 37 (25.7) 2 (14.3) 38(25.7)
50- 59 8 (28.6) 43 (36.4) 2(20.0) 46 (31.9) 5 (35.7) 47(31.8)
≥ 60 11 (39.3) 28 (23.7) 2(20.0) 36 (25.0) 3 (21.4) 39(26.4)
Gender
Male 11 (39.3) 39 (33.1)
0.391 0.532
4(40.0) 51 (35.4)
NA NA
9 (64.3) 49 (33.1)
NA NA
Female 17 (60.7) 79 (66.9) 6(60.0) 93 (64.6) 5 (35.7) 99 (66.9)
Race
Malay 19 (67.9) 75 (63.6)
0.182 0.669
8(80.0) 94 (65.3)
NA NA
9(64.3) 99(66.9)
0.919 0.233
Non-Malay 9 (32.1) 43 (36.4) 2(20.0) 50 (34.7) 5(35.7) 49(33.1)
Co-morbidities
Hypertension 21 (75.0) 69 (58.5) 2.614 0.106 7(70.0) 87 (60.4) NA NA 9 (64.3) 92 (62.2) 0.025 0.875
Dyslipidaemia 15 (53.6) 59 (50.0) 0.115 0.734 6(60.0) 75 (52.1) NA NA 4(28.6) 81 (54.7) 3.509 0.061
Smoking 2 (7.4)*    13 
(12.0)**
NA NA
0(0.00)#  14 (10.5)## NA NA 4 (28.6) 12 (8.8)$ NA NA
*N=27Х   **N=108    #N=9       ##N=133       $N=136     NA=not applicable as there were cells with expected count less than 5
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Poor glycaemic control was a significant risk factors for 
the presence of microvascular complications.
Interpretation of findings and comparison to previous 
findings
There is high prevalence of microvascular complications 
(27.7%) found in present study. Literature had consistently 
showed that there was a substantial proportion (ranged 
from 10% to 70%) of T2D patients had presented with 
microvascular complications at time of diagnosis (6, 7, 
9, 14–18). This happened in both developed country 
such as Denmark (prevalence of 18%) (14), United State 
(prevalence of 50% for the underserved underinsured 
patients from Chicago) (18) and developing countries 
such as Egypt (prevalence of about 10%) (15), India 
(prevalence ranged from 10% to 50%) (6, 16, 17) and 
Pakistan (prevalence of about 70%) (9, 17)  The high 
prevalence of microvascular complications at diagnosis 
in our study could imply the delayed diagnosis and 
failure of early detection of T2D in our population 
which was reflected in the results of Malaysia National 
Health and Morbidity Survey (NHMS); half of the 
patients with T2D reported in NHMS were undiagnosed 
cases (4).  Thus, there is a need to promote vigorous 
screening programme to promote early detection of 
T2D. In addition, screening of these complications 
Table IV: Association between clinical profile and microvascular diabetic complications
Clincal profile
Nephropathy Retinopathy Peripheral Neuropathy
Yes
n (%)
No
n (%)
χ2 
value
P value
Yes
n (%)
No
n (%)
χ2 
value
P value
Yes
n (%)
No
n (%)
χ2 
value
P value
BMI (kg/m2) N=27 N=117 N=10 N=142 N=13 N=147
≤ 22.9 0 (0.0) 16 (13.7)
NA NA
1 (10.0) 15 (10.6)
NA NA
3 (23.1) 13 (8.8)
NA NA23.0-27.4 10 (37.0) 28 (23.9) 3(30.0) 34 (23.9) 3 (23.1) 38 (25.9)
≥ 27.5 17 (63.0) 73 (62.4) 6(60.0) 93 (65.5) 7 (53.8) 96 (65.3)
Waist circumference N=27 N=118 N=10 N=142 N=14 N=146
Achieved* 1 (3.7) 15 (12.7)
NA NA
1 (10.0) 17 (12.0)
NA NA
3 (21.4) 15 (10.3)
NA NA
Not achieved 26 (96.3)
103 
(87.3)
9 (90,0) 125 (88.0) 11 (78.6) 131 (89.7)
Blood pressure N=28 N=118 N=10 N=144 N=14 N=148
≤135/75mmHg 3 (10.7) 25 (21.2)
1.601 0.206
2 (20.0) 25 (17.4)
NA NA
4 (28.6) 25 (16.9)
NA NA
>135/75mmHg 25 (89.3) 93 (78.8) 8 (80.0) 119 (82.6) 10 (71.4) 123 (83.1)
Triglyceride N=28 N=118 N=10 N=143 N=14 N=147
≤1.7 17 (60.7) 75 (63.6)
0.079 0.779
6 (60.0) 85 (59.4)
NA NA
9 (64.3) 87 (59.2)
0.138 0.710
>1.7 11 (39.3) 43 (36.4) 4 (40.0) 58 (40.6) 5 (35.7) 60 (40.8)
LDL N=28 N=117 N=10 N=142 N=14 N=146
≤ 2.6 4 (14.3) 26 (22.2)
0.867 0.352
2 (20.0) 26 (18.3)
NA NA
3 (21.4) 28 (19.2)
NA NA
>2.6 24 (85.7) 91 (77.8) 8 (80.0) 116 (81.7) 11 (78.6) 118 (80.8)
HDL N=28 N=117 N=10 N=142 N=14 N=146
Good control# 16 (57.1) 74 (63.2)
0.358 0.550
7 (70.0) 86 (60.6)
NA NA
11 (78.6) 85 (58.2)
2.205 0.138
Poor control 12 (42.9) 43 (36.8) 3 (30.0) 56 (39.4) 3 (21.4) 61 (41.8)
Glycaemic control N=28 N=116 N=9 N=117 N=14 N=145
HbA1c ≤ 6.5% 5 (17.9) 24 (20.7)
0.113 0.737
1 (11.1) 25 (17.6)
NA NA
19   (7.1) 30 (20.7)
NA NA
HbA1c > 6.5% 23 (82.1) 92 (79.3) 8 (88.9) 117 (82.4) 13 (92.9) 115 (79.3)
NA=not applicable as there were cells with expected count less than 5         #Good control= HDL>1 for men and HDL>1.2 for women
*Achieved= waist circumference <80cm for women and waist circumference <90 cm for men
at diagnosis for all newly diagnosed T2D patients are 
required for early detection of these complications and 
better management.
We found nephropathy is the commonest microvascular 
complications, followed by peripheral neuropathy 
and retinopathy.  It was unable to pin-point which 
microvascular complications was more susceptible 
as literature showed the results varied from one study 
to another.  For example two studies from Pakistan 
showed the highest prevalence of microvascular 
complications for peripheral neuropathy (64.6% and 
59.6% respectively) (7, 9); in India, one study found 
nephropathy as the commonest complication (50%) 
(6) whereas other studies from the same country found 
peripheral neuropathy (13%) (16) and retinopathy 
(9.5%) (17) being the commonest microvascular 
complications. A local study from the state of Kelantan, 
Malaysia found retinopathy (14.6%) be the commonest 
microvascular complication presented at diagnoses (8). 
For developed country, a study from Denmark showed 
that the commonest microvascular complication in 
its studied population was retinopathy (13%) and the 
prevalence for nephropathy and peripheral neuropathy 
was only 3% and 4% respectively (14).  The difference 
of the findings could be due to the difference in inherent 
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employed in different studies. 
Majority of newly diagnosed patients in present study had 
poor control of their clinical profiles that showed about 
90% of the patients were overweight or obese and 80% 
of patients did not achieve the target of BP, glycaemic 
and lipid control.  These findings are consistent with 
other studies conducted in Pakistan, India and United 
States (6, 9, 18).  It could be due to the fact that the 
newly diagnosed patients were at the initial state of the 
treatment and optimisation of the control would need 
longer time.
Previous studies have identified that the risk factors 
for microvascular complications for newly diagnosed 
patients were age, triglycerides, HbA1c and BP status 
(14, 17, 18). In present study, poor glycaemic control 
was the only significant predictor for the presence of 
microvascular complications.  This re-emphasized 
the importance of early detection of T2D for timely 
optimisation of the blood sugar to delay or prevent the 
microvascular complications. 
Strength and limitation 
This is a prospective study that enables the researcher 
to examine and capture for all the three microvascular 
complications i.e. retinopathy, nephropathy and 
peripheral neuropathy as compared to other studies that 
used the retrospective record review which more at risk 
of missing record. 
Limitation of this study includes a relatively small 
sample size and the convenient sampling of the clinics. 
Sample size calculation was based on the prevalence 
of peripheral neuropathy only, and the sample size 
needed for other microvascular complications might not 
be similar. Thus, the results need to be interpreted with 
caution. Nevertheless, the results of this study provide 
an insight on the impact of delayed diagnosis.  Future 
studies could use randomised sampling and covers 
more clinics and states for representative population. 
There were 16 cases did not turn up for the 2nd sample 
collection of urine albumin/microalbumin after the 
initial positive of urine albumin/microalbumin and thus 
unable to confirm their status of nephropathy.  This could 
underestimate the total patients who have developed at 
least one microvascular complication.
 
CONCLUSION
There is high prevalence of microvascular complications 
among the newly diagnosed T2D patients. Hence 
screening of these complications at diagnosis for all 
newly diagnosed T2D patients are required at clinic 
level for early detection and better management. There 
is a need to develop appropriate strategies to increase the 
awareness and early detection of T2D at the community 
level for prevention or delaying the development of 
microvascular complications. 
Table V: Factors associated with microvascular complications
Variable OR 95%CI P - value
Glycaemic control
    HbA1c ≤ 6.5% ref
    HbA1c > 6.5% 5.843 1.466, 23.288 0.012
Lipid control (mmol/L)
    LDL ≤ 2.6 ref
    LDL >2.6 1.538 0.503,4.703 0.451
    HDL good control# ref
    HDL poor control 0.579 0.251, 1.338 0.201
    TG ≤ 1.7 ref
    TG  >1.7 0.716 0.307, 1.672 0.441
Blood pressure control 
(mmHg)
   BP ≤ 135/75 ref
   BP > 135/75 1.171 0.394, 3.475 0.776
Waist circumference (cm)
   Achieved* ref
   Not achieved 1.727 0.304, 9.801 0.537
BMI (kg/m2)
    <22.9 ref
     23-27.4 1.374 0.218, 8.656 0.735
     ≥ 27.5 0.759 0.118, 4.881 0.771
Smoking 
     Yes ref
     No 0.528 0.115, 2,426 0.412
Dyslipideamia 
      No ref
      Yes 0.777 0.339, 1.780 0.550
Hypertension
       No ref
       Yes 2.244 0.763, 6.599 0.142
Race
      Non-Malay ref
      Malay 0.888 0.356, 2.213 0.798
Age group
   <45 ref
    45-54 0.483 0.161, 1.445 0.193
    55-64 0.840 0.257, 2.750 0.773
     ≥ 65 0.330 0.059, 1.833 0.205
Gender
    Male ref
    Female 0.679 0.260, 1.770 0.429
#Good control= HDL>1 for men and HDL>1.2 for women
*Achieved= waist circumference <80cm for women and waist circumference <90 cm for 
men
Multivariate logistic regression analysis:  Nagelkerke R square= 0.168
ethnic or genetic susceptibility of an individual to 
the complications as well as exposure of difference 
lifestyle (dietary habit and physical activities) from one 
population to the other that could contribute to the risk 
factors for development of microvascular complications. 
In addition, the variability in the prevalence may be 
due to difference in age group of studied population, 
setting (hospital vs primary care) and diagnostic criteria 
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